Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Get Free Report) major shareholder Millennium Management Llc sold 8,151 shares of the business’s stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $31.01, for a total value of $252,762.51. Following the completion of the sale, the insider owned 133,986 shares of the company’s stock, valued at $4,154,905.86. This trade represents a 5.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Millennium Management Llc also recently made the following trade(s):
- On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $28.12, for a total value of $52,218.84.
- On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.81, for a total transaction of $13,539.05.
- On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total transaction of $23,629.68.
- On Monday, March 30th, Millennium Management Llc bought 9,533 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $25.86 per share, for a total transaction of $246,523.38.
- On Friday, March 27th, Millennium Management Llc bought 15,321 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $26.61 per share, for a total transaction of $407,691.81.
- On Thursday, March 26th, Millennium Management Llc acquired 5,731 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $28.62 per share, for a total transaction of $164,021.22.
- On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $25.49, for a total value of $40,554.59.
- On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $31.65, for a total value of $36,397.50.
- On Wednesday, April 1st, Millennium Management Llc acquired 6,175 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $34.49 per share, for a total transaction of $212,975.75.
- On Tuesday, March 31st, Millennium Management Llc purchased 6,005 shares of Sensei Biotherapeutics stock. The stock was purchased at an average cost of $28.16 per share, for a total transaction of $169,100.80.
Sensei Biotherapeutics Price Performance
Shares of NASDAQ:SNSE opened at $20.43 on Friday. The business’s 50 day moving average price is $28.89 and its 200-day moving average price is $17.87. The firm has a market capitalization of $27.38 million, a PE ratio of -0.14 and a beta of -0.18. Sensei Biotherapeutics, Inc. has a 1 year low of $5.25 and a 1 year high of $36.76.
Hedge Funds Weigh In On Sensei Biotherapeutics
A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Free Report) by 10.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the period. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 10.50% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the company. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Wall Street Zen lowered shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Leerink Partners began coverage on shares of Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 price target on the stock. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $40.00.
Check Out Our Latest Analysis on SNSE
Key Headlines Impacting Sensei Biotherapeutics
Here are the key news stories impacting Sensei Biotherapeutics this week:
- Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
- Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.
The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.
Featured Stories
- Five stocks we like better than Sensei Biotherapeutics
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
